Abstract Introduction There is an imminent need for faster-acting and more effective antidepressants beyond the monoaminergic hypothesis. Methods We systematically searched the US Clinical Trials registry for antidepressant compounds with completed phase II and III trials. Compounds that demonstrated significant superiority over placebo in the primary outcome measure in the latest phase of...
Depression treatments succeed with many but leave others unimproved, and they can generate concerns about side effects, time, and cost. Psilocybin has generated media attention and empirical support for antidepressant effects, but lay impressions of its effectiveness are unclear. Although perceptions of treatment credibility contribute to outcome, beliefs about the credibility of...
Back to table of contents Previous article Next article Med CheckFull AccessMed Check: Clozapine REMS; Aduhelm; BNC210 Fast Tracked for Social Anxiety Disorder; and MoreTerri D'ArrigoTerri D'ArrigoPublished Online:29 Dec 2021https://doi.org/10.1176/appi.pn.2022.1.2Aduhelm Shows Promise for Alzheimer's DiseaseTwo phase 3 clinical trials of Aduhelm (aducanumab) showed a correlation between plasma...
Survey-based studies suggest naturalistic psychedelic use provides mental health benefits similar to those observed in clinical trials. The current study sought to confirm these findings in a large group of psychedelic users and to conduct a novel examination of associations between amount of psychedelic use and behavioral outcomes, as well as frequency of harms ascribed to psychedelic use. A...
Depression is highly prevalent and represents the leading cause of global disability and primary contributor to overall global burden of disease. Several lines of evidence from early-phase experimental trials suggest that serotonergic psychedelics, particularly psilocybin, with therapeutic support show great promise in the treatment of depression with large effect sizes. Neuroimaging data have...
The largest trial to date of the psychedelic drug psilocybin has shown that, alongside psychological support, a single 25mg dose may improve the symptoms of treatment-resistant depression. The phase II study, published in the New England Journal of Medicine on 3 November 2022, was conducted across 22 sites in 10 countries, including the UK, between […]
Given the number of people who are treated for depression each year and the knowledge that treatments work differently for everyone, there is a pressing need to provide a variety of treatment options. Although psychedelic research had been halted for a few decades due to recreational abuse, there has been revived interest due to its therapeutic potential in the treatment of mood disorders and...
Psychedelics such as psilocybin have recently gained remarkable interest in both the specialist literature and the lay press because studies suggest that these substances may have great therapeutic potential in various psychiatric disorders, including major depression. However, clinical trials with psychedelic drugs pose particular methodological challenges to researchers, some of which differ...
Introduction: Psychedelics have seen various labels: mystical sacrament aids, potential interrogation tools for the Cold War, agents for social change in the Hippie counter movement, a panacea for various mental disorders, and a tool to “hack” of the psyche. This has led to their reputation as both societal threat and a psychopharmacological breakthrough. After the loss of data on over 1000...
There is a serious need for novel therapies that treat individuals with depression, including major depressive disorder (MDD) and treatment-resistant depression (TRD). An emerging body of research has demonstrated that psychedelic drugs such as psilocybin, combined with supportive psychotherapy, exert rapid and sustained antidepressant effects. The use of psychedelics is not new: they have a...